Axena Health Begins First-of-Its-Kind Global Study of Female Incontinence

Axena Health, Inc. (Axena Health), a women’s health medical device company focused on scalable treatments for female pelvic health, announced today a large-scale study that will investigate the burdens of incontinence on women in low- and middle-income countries to support equitable access to treatment. The first-of-its-kind study will examine how women could access treatment within local healthcare delivery systems and in a manner that accommodates cultural norms. Study results will be available in late 2023 and will inform the development of new treatment options based on the Leva^® Pelvic Health System, a digital health treatment for urinary incontinence (UI) with published studies supporting its effectiveness, including durable, long-term symptom relief. Read more.

Source: Yahoo! Finance, May 19, 2023

Megola Completes Successful Pilot Scale-Up Field Testing of its Patent-Pending Odor Control (SAPs) for Baby Diapers, Adult Incontinence and Feminine Hygiene Products

Megola, Inc. (“MGON”, “Company”) a Consortium Group of Health Technologies and Eco-Friendly Product Lines announced the successful completion of its Pilot Scale-up Field Testing with its patent-pending Odor Control (SAPs) for Baby Diapers, Adult Incontinence and Feminine Hygiene Products. The odor control personal hygiene products were provided to a group of incontinent human volunteers in the USA. Superabsorbent Polymer granules (SAP) are used annually in diapers and pads of all types, in a global industry with an annual turnover of more than $100 billion. “It’s been a long time coming but controlling embarrassing odors from incontinence garments and feminine hygiene products is about to become a reality at last….” Read more.

Source: StreetInsider.com, May 8, 2023

Acupuncture for Women With Overactive Bladder

The most common symptom of an overactive bladder is a sudden, uncontrolled need or urge to urinate; followed by the need to urinate excessively throughout the day and night, independent of fluid intake. In women, causes of overactive bladder are varied, but the common consequence, beyond the physical manifestations, are frustration and embarrassment. While medications designed to relax the bladder remain a frontline treatment option, research continues to show the potential of nonpharmaceutical options – including acupuncture. Case in point: a 2023 research review that concludes acupuncture is effective and safe for treating overactive bladder. Read more.

Source: Acupunture Today, May/June 2023

World’s First Bladder Transplant Will Be Performed By Both Human and Robot Surgeons

A team of urologists at Keck Medicine of the University of South California (USC) is conducting a clinical trial that will soon lead to the first-ever bladder transplant operation in humans. The doctors are currently in the process of selecting participants for their trials. If successful, such operations would provide relief to millions of people around the globe who live with bladder-related disorders. Inderbir Gill, principal investigator and executive director at Keck Medicine USC Urology, said, “We could be on the verge of a medical advance that has the potential to revolutionize how we treat terminally compromised bladders.” Read more.

Source: Interesting Engineering, May 2, 2023

Women’s Health Leader Elidah Launches Game-changing ELITONE URGE Device To Treat Overactive Bladder

Providing the same relief for overactive bladder (OAB) that they’ve become known for in the stress urinary incontinence arena, MedTech Elidah is excited to introduce their newest product, ELITONE URGE (https://elitone.com/products/), the first and only non-intrusive treatment for urge incontinence. This latest device, a natural successor to ELITONE, is specified to treat urgency bladder leaks that afflict 33 million women in the United States alone. ELITONE URGE is an external, non-implanted muscle stimulator that outputs signals to calm the muscles and nerves that cause urgency or OAB leaks. The patented design maximizes comfort and efficacy, while being discreet and wearable under clothes, for the perfect urge incontinence therapy.

Source: Globe Newswire, May 2, 2023

Clinical Study Results of the BlueWind System for Patients with Overactive Bladder Featured at the 2023 AUA Annual Meeting

BlueWind Medical, Ltd., the developer of a transformative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), today announced results from the OASIS pivotal trial evaluating the safety and efficacy of the BlueWind System in the treatment of OAB. The results were featured in the late-breaking session (LBA01-05) at the American Urological Association (AUA) 2023 Annual Meeting in Chicago on Sunday, April 30^th. Read more.

Source: PRNewswire, May 1, 2023

AUA, SUFU Release an Amendment to the Female Stress Urinary Incontinence Guideline

Today, the American Urological Association (AUA), in partnership with the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), released the 2023 clinical practice guideline amendment for the surgical treatment of female stress urinary incontinence (SUI). SUI is a common problem experienced by many women. About 1 in 3 women suffer from SUI at some point in their lives, and the chance of having urinary incontinence increases with age. The updated guideline has 24 recommendations that provide a clinical framework for the assessment and treatment of SUI in women. Read more and access the new guideline.

Source: PRNewswire, April 25, 2023

Axonics Acquires Tech to Expedite Placement of Implantable Leads in Sacral Neuromod

Axonics (Nasdaq:AXNX) today announced it acquired lead placement technology from Radian to speed up the placement of implantable leads for sacral neuromodulation. Axonics acquired the assets of Radian from Intermed Labs for an undisclosed amount. The company expects the product to receive FDA clearance and be available on a commercial basis in mid-2024. Read more.

Soure: MassDevice.com, April 24, 2023

UroMems Granted Safer Technologies Program Designation from FDA for Smart Implant to Treat Stress Urinary Incontinence

UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that they have received Safer Technologies Program (STeP) designation from the U.S. Food and Drug Administration (FDA) for UroActive Smart Continence Therapy. STeP is a collaborative program intended to help reduce the time it takes to develop and obtain marketing authorization for eligible devices. Read more.

Source: PRNewswire, April 20, 2023

woman pushing another woman in wheelchair caregiver

Touching Film for TENA Goes Behind Closed Doors to Show the Reality of Family Carers

Around one in ten people already look after a loved one [1], yet new research conducted by Essity owned incontinence brand TENA reveals that only 50% of people who provided extended family care considered themselves a ‘carer’. This lack of perception is largely down to those doing the care not acknowledging themselves as ‘carers’ and, as a result, they feel more alone and unaware of the support available. The research, conducted with Ketchum, is part of TENA’s new global campaign #NoLoveLikeIt, which sees the brand also partnering with Carers UK. Committed to providing care for both caregiver and receiver, TENA delved deep into qualitative and quantitative research to understand the realities of caring, which will become a reality for most of us at some point, as populations age and more care is provided in home by families. Read more.

Source: lbbonline, April 12, 2023